Bioequivalence of daclatasvir hydrochloride tablets in healthy Chinese subjects.

MLA

Shi, Li-Ping, et al. “Bioequivalence of Daclatasvir Hydrochloride Tablets in Healthy Chinese Subjects.” International Journal of Clinical Pharmacology and Therapeutics, vol. 59, no. 8, Aug. 2021, pp. 585–92. EBSCOhost, https://doi.org/10.5414/CP203895.

APA

Shi, L.-P., Yang, X., Liu, F., Yin, J.-G., Yu, J.-M., Zhang, J., Wang, H., Zou, C., & Jiang, M. (2021). Bioequivalence of daclatasvir hydrochloride tablets in healthy Chinese subjects. International Journal of Clinical Pharmacology and Therapeutics, 59(8), 585–592. https://doi.org/10.5414/CP203895

Chicago

Shi, Li-Ping, Xue Yang, Fang Liu, Jun-Gang Yin, Jing-Mei Yu, Jun Zhang, Hui Wang, Chong Zou, and Meng Jiang. 2021. “Bioequivalence of Daclatasvir Hydrochloride Tablets in Healthy Chinese Subjects.” International Journal of Clinical Pharmacology and Therapeutics 59 (8): 585–92. doi:10.5414/CP203895.